Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Title
Intervention Indication Therapeutic Area Year Actions
Rucaparib for metastatic castration-resistant prostate cancer associated with homologous recombination deficiency Rucaparib (Rubraca; PF-1367338) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Rucaparib maintenance therapy for ovarian, fallopian tube or primary peritoneal cancer after frontline platinum-based chemotherapy Rucaparib (Rubraca; PF-1367338) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2022 View  |  Download
Rucaparib with nivolumab for the maintenance treatment of newly diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Breast cancer Breast Cancer 2022 View  |  Download
Ruxolitinib cream for vitiligo Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Vitiligo Dermatology 2021 View  |  Download
Ruxolitinib for acute graft versus host disease (aGvHD) Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2019 View  |  Download
Ruxolitinib for chronic graft versus host disease (cGvHD) Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2019 View  |  Download
Ruxolitinib for grades II-IV treatment-naïve or steroid-refractory acute graft versus host disease Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2023 View  |  Download
Ruxolitinib for treating chronic graft versus host disease after allogeneic stem cell transplant in paediatric patients Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2023 View  |  Download
SA-237 for neuromyelitis optica and neuromyelitis optica spectrum disorders Satralizumab (SA237; RG6168) Neuromyelitis optica , Neuromyelitis optica spectrum disorders Neurology , Ophthalmology 2017 View  |  Download
Sabatolimab in addition to azacitidine for myelodysplastic syndromes – first-line Azacitidine (Vidaza; CC-486) , Sabatolimab (MBG453) Chronic myelomonocytic leukaemia (CMML) , Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2021 View  |  Download
1 2 88 89 90 91 92 113 114
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications